FORT WORTH, Texas, Sept. 3 /PRNewswire-FirstCall/ -- Wound Care
Innovations, LLC, a subsidiary of Wound Management Technologies, Inc.,
(OTC Bulletin Board: WNDM), announced today that it has signed an agreement
with Dr. Leland Shapiro, MD to conduct studies on their advanced wound care
collagen product, CellerateRx(R). Dr. Shapiro, Associate Professor of
Medicine at the University of Colorado Denver School of Medicine and the
Denver Veteran's Affairs Medical Center, has published extensively on factors
affecting cell cytokine induction and suppression. He has over 35 original
publications in peer reviewed journals as well as reviews and book chapters in
leading authoritative texts. "Dr. Shapiro is a leading authority and
recognized in his field worldwide," stated Cathy Bradshaw, President of Wound
Care Innovations. "We are very excited about this agreement and the
opportunity to work with Dr. Shapiro and his team in these evaluations of
CellerateRx(R)."
About Wound Management Technologies, Inc.:
Wound Management Technologies, Inc. (WNDM), with its corporate
headquarters in Fort Worth, Texas, markets and distributes wound care products
to the healthcare market under patented technology licensed to the Company.
The Company is positioned and seeks to be a leading provider of wound care
products. For more information on the Company please visit the Company's
Website at www.Celleraterx.com .
"Safe Harbor" Statement: Under The Private Securities Litigation Reform
Act of 1995: The statements in the press release that relate to the company's
expectations with regard to the future impact on the company's results from
new products in development are "forward-looking statements," within the
meaning of the Private Securities Litigation Reform Act of 1995. Since this
information may contain statements that involve risk and uncertainties and are
subject to change at any time, the company's actual results may differ
materially from expected results. This document may contain forward-looking
statements concerning the Company's operations, current and future performance
and financial condition. These items involve risks and uncertainties such as
product demand, market and customer acceptance, the effect of economic
conditions, competition, pricing, the ability to consummate and integrate
acquisitions, and other risks and uncertainties detailed in the Company's SEC
filings. The Company undertakes no obligation to revise any of these
statements to reflect the future circumstances or the occurrence of
unanticipated events.
Product Information Shareholder Relations
Cathy Bradshaw Lucy Singleton
President Secretary
954-315-9242 817-820-7080
SOURCE Wound Management Technologies, Inc.
